Efficacy & Safety of CG-100 Intraluminal Bypass Device in Colorectal & Coloanal Anastomoses

Cancer
Joseph Carmichael
Efficacy and Safety of the CG-100 Intraluminal Bypass Device in Colorectal and Coloanal Anastomoses: Prospective, Open Label, Randomized Trial
Colon
Rectum

Study Description

In this study, Colospan is investigating the use of the CG-100 Intraluminal Bypass Device as a treatment option that could protect the anastomotic site from faecal contact in order to give the site time to heal (approximately 10 days) in order to prevent anastomotic leaks. One benefit of the CG-100 Intraluminal Bypass Device is that it may reduce the occurrence of unnecessary diverting stoma procedures. The CG-100 Intraluminal Bypass Device is a single use, removable, temporary tube that is placed inside the colon and through the anastomosis during the colorectal surgery. The device was developed by Colospan and is intended to allow faecal material pass over the anastomosis site without contact.

Eligibility

  • Patients must be 22-70 years of age and diagnosed with colorectal cancer.
  • Patient is scheduled for elective open, laparoscopic, or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis.
  • Patients who are scheduled to receive a protective stoma during their primary planned operation.
  • Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis, or extensively spread inflammatory bowel disease.
  • Patient has been taking regular systemic/steroid medication in the last 6 months.
  • Pregnant or nursing female patients. Female patients of child-bearing potential must have negative pregnancy test done within 7 days.
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.